JP2013522236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522236A5 JP2013522236A5 JP2012557280A JP2012557280A JP2013522236A5 JP 2013522236 A5 JP2013522236 A5 JP 2013522236A5 JP 2012557280 A JP2012557280 A JP 2012557280A JP 2012557280 A JP2012557280 A JP 2012557280A JP 2013522236 A5 JP2013522236 A5 JP 2013522236A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- biological sample
- cell
- lymphoma
- activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31367010P | 2010-03-12 | 2010-03-12 | |
| US61/313,670 | 2010-03-12 | ||
| PCT/US2011/028097 WO2011112933A1 (en) | 2010-03-12 | 2011-03-11 | Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013522236A JP2013522236A (ja) | 2013-06-13 |
| JP2013522236A5 true JP2013522236A5 (https=) | 2014-04-24 |
Family
ID=43799739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012557280A Pending JP2013522236A (ja) | 2010-03-12 | 2011-03-11 | レナリドミドを使用する非ホジキンリンパ腫の治療方法、並びに予測因子としての遺伝子及びタンパク質バイオマーカー |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20110223157A1 (https=) |
| EP (1) | EP2544687A1 (https=) |
| JP (1) | JP2013522236A (https=) |
| KR (1) | KR20130038838A (https=) |
| CN (1) | CN103068386A (https=) |
| AR (1) | AR080505A1 (https=) |
| AU (1) | AU2011224166B2 (https=) |
| CA (1) | CA2792872A1 (https=) |
| MX (1) | MX2012010367A (https=) |
| TW (1) | TWI509247B (https=) |
| WO (1) | WO2011112933A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2436387B1 (en) | 2009-05-25 | 2018-07-25 | Celgene Corporation | Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex |
| AU2012249491B2 (en) | 2011-04-29 | 2016-12-15 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| AU2013299627C1 (en) * | 2012-08-09 | 2018-05-31 | Celgene Corporation | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| US20150167097A1 (en) | 2012-09-20 | 2015-06-18 | Emory University | CLASSIFIERS OF NF-kB PATHWAY ACTIVATION, DEVICES, AND METHODS OF USE THEREOF |
| NZ629456A (en) * | 2013-04-17 | 2017-06-30 | Signal Pharm Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
| WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| EP2991651A1 (en) | 2013-05-03 | 2016-03-09 | Celgene Corporation | Methods for treating cancer using combination therapy |
| LV14985B (lv) | 2013-10-14 | 2015-06-20 | Latvijas Organiskās Sintēzes Institūts | Lenalidomīda iegūšanas process |
| US20160282354A1 (en) | 2013-11-08 | 2016-09-29 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| EP3077547A4 (en) * | 2013-12-06 | 2017-11-08 | Celgene Corporation | Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| US10245266B2 (en) * | 2014-05-19 | 2019-04-02 | Celgene Corporation | 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
| EP3827836A1 (en) | 2014-06-27 | 2021-06-02 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| WO2017044793A1 (en) | 2015-09-11 | 2017-03-16 | The Brigham And Women's Hospital, Inc. | Methods of characterizing resistance to modulators of cereblon |
| WO2017059108A1 (en) * | 2015-09-29 | 2017-04-06 | Htg Molecular Diagnostics, Inc. | Methods for subtyping diffuse b-cell lymphoma (dlbcl) |
| WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| KR20180095094A (ko) | 2016-01-08 | 2018-08-24 | 셀진 코포레이션 | 암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도 |
| US20190231757A1 (en) * | 2016-07-13 | 2019-08-01 | Takeda Pharmaceutical Company Limited | Combination of spleen tyrosine kinase inhibitors and other therapeutic agents |
| WO2018144445A1 (en) * | 2017-01-31 | 2018-08-09 | Celgene Corporation | Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds |
| TWI787284B (zh) | 2017-06-22 | 2022-12-21 | 美商西建公司 | 以b型肝炎病毒感染表徵之肝細胞癌之治療 |
| IL281845B2 (en) | 2018-10-01 | 2025-06-01 | Celgene Corp | Combination therapy comprising 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and daratumumab for the treatment multiple myeloma |
| WO2020076936A1 (en) * | 2018-10-10 | 2020-04-16 | Celgene Corporation | Methods of classifying diffuse large b-cell lymphoma |
| WO2025118133A1 (zh) * | 2023-12-05 | 2025-06-12 | 浙江普洛家园药业有限公司 | 一种(s)-来那度胺-5-位衍生物及其合成方法和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| JPS63500636A (ja) * | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) * | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| EP0456950A1 (en) * | 1990-05-16 | 1991-11-21 | CONTRAVES ITALIANA S.p.A. | Actuator for restraint/release (R/R) devices, particularly for space applications |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| CA2752124A1 (en) * | 2002-05-17 | 2003-11-27 | Celgene Corporation | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer |
| CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
| US8367633B2 (en) * | 2007-08-06 | 2013-02-05 | University Of Rochester | Methods of treating B-cell cancers |
| US7893045B2 (en) * | 2007-08-07 | 2011-02-22 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
| EP2235535B1 (en) * | 2007-12-07 | 2014-11-12 | Celgene Corporation | Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma |
-
2011
- 2011-03-11 KR KR1020127026568A patent/KR20130038838A/ko not_active Withdrawn
- 2011-03-11 JP JP2012557280A patent/JP2013522236A/ja active Pending
- 2011-03-11 AU AU2011224166A patent/AU2011224166B2/en not_active Ceased
- 2011-03-11 EP EP11709300A patent/EP2544687A1/en not_active Withdrawn
- 2011-03-11 TW TW100108463A patent/TWI509247B/zh not_active IP Right Cessation
- 2011-03-11 AR ARP110100782A patent/AR080505A1/es unknown
- 2011-03-11 US US13/046,527 patent/US20110223157A1/en not_active Abandoned
- 2011-03-11 WO PCT/US2011/028097 patent/WO2011112933A1/en not_active Ceased
- 2011-03-11 MX MX2012010367A patent/MX2012010367A/es not_active Application Discontinuation
- 2011-03-11 CN CN2011800230775A patent/CN103068386A/zh active Pending
- 2011-03-11 CA CA2792872A patent/CA2792872A1/en not_active Abandoned
-
2015
- 2015-03-03 US US14/636,949 patent/US20150174114A1/en not_active Abandoned
- 2015-09-18 US US14/858,594 patent/US20160008344A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013522236A5 (https=) | ||
| US12076324B2 (en) | Cancer treatments using combinations of CDK and ERK inhibitors | |
| Gild et al. | Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells | |
| AU2015240465B2 (en) | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer | |
| JP2014510078A5 (https=) | ||
| JP2020073520A (ja) | Ｗｅｅ１阻害剤を用いた癌を処置する方法 | |
| US20140296176A1 (en) | Combination cancer therapy with an hsp90 inhibitor and an antimetabolite | |
| RU2013145524A (ru) | Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона | |
| EP3024457A1 (en) | Compositions to improve the therapeutic benefit of bisantrene | |
| EP4085053A1 (en) | Treatment of cancer with cdk12/13 inhibitors | |
| Azanza et al. | Comparative pharmacology of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia | |
| Lawasut et al. | Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets | |
| WO2025076109A1 (en) | Use of elesclomol to treat clear-cell ovarian cancers with mutations in arid1a | |
| WO2023202563A1 (en) | Akt inhibitor in combination with pim kinase inhibitor | |
| US11155879B2 (en) | Method of predicting effects of CDC7 inhibitor | |
| JP2019532934A (ja) | 卵巣癌を治療するための方法 | |
| WO2025207503A1 (en) | Inhibitors of polo-like kinase 4 (plk4) for the treatment of cancer | |
| CA3036568C (en) | Methods for treating ovarian cancer | |
| TW202408514A (zh) | 用於治療癌症的表皮生長因子受體酪胺酸激酶抑制劑 | |
| CN116940365A (zh) | 慢性髓性白血病干细胞抑制剂 | |
| EP2436762A1 (en) | Method for prediction of therapeutic effect of chemotherapy employing expression level of dihydropyrimidine dehydrogenase gene as measure | |
| Albert | Histone Deacetylase Inhibitors are Effective Therapeutic Agents in Nasopharyngeal Carcinoma Cells | |
| HK40120025A (en) | Cancer treatments using combinations of cdk and erk inhibitors | |
| HK40020609B (en) | Method of predicting effects of cdc7 inhibitor | |
| HK40020609A (en) | Method of predicting effects of cdc7 inhibitor |